HSA
ALXN

Hussman Strategic Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Hussman Strategic Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,200
Closed -$1.14M – 368
2021
Q2 		$1.14M Sell
6,200
-1,000
-14% -$172K 0.24% 163
2021
Q1 		$1.1M Buy
+7,200
New +$1.11M 0.23% 169
2020
Q3 		– Sell
-10,300
Closed -$1.16M – 322
2020
Q2 		$1.16M Sell
10,300
-200
-2% -$21.2K 0.29% 133
2020
Q1 		$943K Hold
10,500
– – 0.25% 158
2019
Q4 		$1.14M Hold
10,500
– – 0.36% 105
2019
Q3 		$1.03M Buy
10,500
+500
+5% +$56.4K 0.29% 127
2019
Q2 		$1.31M Sell
10,000
-10,000
-50% -$1.29M 0.37% 107
2019
Q1 		$2.7M Hold
20,000
– – 0.66% 47
2018
Q4 		$1.95M Buy
+20,000
New +$2.36M 0.47% 94

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Hussman Strategic Advisors's ALXN Position: Q3 2021 in Review

Hussman Strategic Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6,200 shares — an estimated $1.14M sold.

Hussman Strategic Advisors first reported a position in ALXN in Q4 2018 and held it in 9 quarters. The position peaked at $2.7M in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Hussman Strategic Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 6,200 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.14M.
  • Hussman Strategic Advisors first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 9 quarters.
  • Hussman Strategic Advisors's Alexion Pharmaceuticals position peaked at $2.7M in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Hussman Strategic Advisors's 13F filing for Q3 2021, filed 1 Nov 2021.